The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial

SR Susai; D Mongan; C Healy; M Cannon; B Nelson; C Markulev; MR Schäfer; M Berger; N Mossaheb; M Schlögelhofer; S Smesny; IB Hickie; GE Berger; EYH Chen; L de Haan; DH Nieman; M Nordentoft; A Riecher-Rössler; S Verma; A Thompson; AR Yung; PD McGorry; M Föcking; D Cotter; GP Amminger

Journal article

The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial

SR Susai, D Mongan, C Healy, M Cannon, B Nelson, C Markulev, MR Schäfer, M Berger, N Mossaheb, M Schlögelhofer, S Smesny, IB Hickie, GE Berger, EYH Chen, L de Haan, DH Nieman, M Nordentoft, A Riecher-Rössler, S Verma, A Thompson Show all

Brain Behavior and Immunity | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2022

DOI: 10.1016/j.bbi.2021.09.018

Abstract

Background: There is increasing evidence that dysregulation of polyunsaturated fatty acids (FAs) mediated membrane function plays a role in the pathophysiology of schizophrenia. Even though preclinical findings have supported the anti-inflammatory properties of omega-3 FAs on brain health, their biological roles as anti-inflammatory agents and their therapeutic role on clinical symptoms of psychosis risk are not well understood. In the current study, we investigated the relationship of erythrocyte omega-3 FAs with plasma immune markers in a clinical high risk for psychosis (CHR) sample. In addition, a mediation analysis was performed to examine whether previously reported associations betwee..

View full abstract

University of Melbourne Researchers

Barnaby Nelson Author

Connie Markulev Author

Eric Yu Hai Chen Author

Andrew Thompson Author

Related Projects (6)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

RCT OF OMEGA-3 FATTY ACIDS AS TREATMENT OF SUBTHRESHOLD SYMPTOMS IN YOUNG PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS

Omega-3 fats are a type of polyunsaturated fat which has long been thought to be beneficial for health. The body cannot make its own omega-3..

LIPID BIOLOGY FOR PREDICTION AND PREVENTION OF PSYCHOTIC DISORDERS AND PERSISTENT DEPRESSION IN YOUNG PEOPLE

My vision for the next 5 years is to establish ω-3PUFAs as a first-line treatment for indicated prevention of psychosis and persistent depre..

MAPPING AND TREATING EARLY CLINICAL STAGES OF MENTAL DISORDERS DURING TRANSITION TO ADULTHOOD

The research proposed in this Fellowship is aimed at young people with emerging mental ill-health. The specific goals and targets are to for..

CLINICAL PREDICTORS OF OUTCOME IN THE ULTRA HIGH RISK FOR PSYCHOSIS ("PRODROMAL") POPULATION

This area of research is concerned with improving our ability to identify young help-seeking patients who are most at risk of developing psy..

CAN WE PREDICT PSYCHOSIS AND CAN IT BE PREVENTED?

It remains unclear what the causes of schizophrenia and other psychotic disorders are and what the most effective interventions are for prev..

Grants

Awarded by Bristol-Myers Squibb

Funding Acknowledgements

This publication has emanated from research supported by Health Research Board (HRB) [to DC, MF, MC] under grant number HRB/HRA/PHR/2015-1293. The research was funded in part by a research grant from Science Foundation Ireland (SFI) under Grant Number 16/RC/3948 and co-funded under the European Regional Development Fund and by FutureNeuro industry partners. The immune marker study was supported by Orygen, Australia. DM is a Fellow on the Irish Clinical Academic Training (ICAT) Programme which is supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. MC and CH were supported by a European Research Council Consolidator grand awarded to M Cannon (iHEAR, Grant Code: 724809). The NEURAPRO clinical trial (anzctr.org.au Identifier:12608000475347) was supported by the Stanley Medical Research Institute (Grant No. 07TGF-1102 [to PDM, GPA, and BN]), National Health and Medical Research Council Australia (Grant No. 566529 [to PDM, IBH, ARY, and GPA], Grant No. 509388 [to GPA and PDM], Senior Research Fellowship Grant No. 1080963 [to GPA], Senior Research Fellowship Grant No. 566593 and Principal Research Fellowship Grant No. GNT1136829 [to ARY], Career Development Fellowship Grant No. 1027532 and Senior Research Fellowship No. 1137687 [to BN], and Senior Principal Research Fellowship Grant No. 1060996 [to PDM]), Colonial Foundation (to PDM), and National Alliance for Research on Schizophrenia and Depression (to PDM). PDM reports receiving unrestricted research funding from AstraZeneca, Eli Lilly and Company, Janssen-Cilag, Pfizer, and Novartis and honoraria for educational activities with AstraZeneca, Eli Lilly and Company, Janssen-Cilag, Pfizer, Bristol-Myers Squibb, Roche Holding AG, and the Lundbeck Institute.